I'm LongbridgeAI, I can summarize articles.Oxford Biomedica PLC announced the admission to trading of 7,363 new ordinary shares on the London Stock Exchange's Main Market. These shares were issued under the OXB Deferred Bonus Plan and Sharesave Scheme between June 24 and August 7, 2026. The total number of admitted shares is now 121,044,504. The new shares are confirmed as fungible with existing ones.
RNS Number : 7451Q Oxford Biomedica PLC 14 August 2026
OXB
Admission to Trading
In accordance with the Financial Conduct Authority's Prospectus Rules: Admission to Trading on a Regulated Market (PRM) sourcebook 1.6.4R, OXB notifies the market that following shares have been admitted to trading pursuant to their allotment under the OXB Deferred Bonus Plan (DBP) and OXB Sharesave Scheme (SAYE) as follows:
Issuer name: | OXFORD BIOMEDICA PLC |
Issuer LEI: | 213800S1GVQNXQ15K851 |
Regulated market on which the shares have been admitted to trading: | Main Market for listed securities of the London Stock Exchange |
Name, type and ISIN of the shares: | Ordinary shares of 50p each GB00BDFBVT43 |
Number of further shares admitted to trading covered by the notification: | 7,363 |
Total number of shares admitted to trading (including the new shares): | 121,044,504 |
Confirmation that the new shares are fungible with existing shares already admitted to trading: | Confirmed |
Date range covered by the notification: | 24 June 2026 - 7 August 2026 |
-Ends-
Enquiries:
OXB:
Natalie Walter, Chief Legal Officer and Group Company Secretary
T: +44 (0) 1865 783 000 / E: cosec@oxb.com
About OXB
OXB is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ADMUSSKRNNUWARR